Navigation Links
Retina Group of New York Now Offers Long-lasting Ozurdex® Treatment for Diabetic Retinopathy
Date:7/14/2014

Hicksville and Hauppauge, NY (PRWEB) July 14, 2014

The Retina Group of New York (RGONY), with offices in Hicksville and Hauppauge, NY, has announced the availability of Ozurdex® (dexamethasone intravitreal implant) as a long-lasting treatment for diabetic macular edema (DME) patients. Ozurdex, a corticosteroid manufactured by Allergan, recently obtained an additional FDA-approved indication for use in diabetic macular edema. Ozurdex was previously approved by the FDA in 2009 for treatment of retinal vascular occlusions and and in 2010 for non-infectious uveitis (inflammation in the eye).

DME, a leading cause of vision loss in diabetic patients, is a condition in which microvascular damage from diabetes leads to leakage in the central portion of the retina, the macula. This causes blurring and loss of vision, and eventually legal blindness. The OZURDEX® biodegradable implant is delivered as an injection, and is administered during an office visit. The medication is slowly released over a period of months, suppressing inflammation, a key factor in DME. On average, patients receiving the medication demonstrate an improvement in vision and less leakage.

According to James M. Maisel, M.D., Chairman of the Retina Group of New York and a vitreoretinal surgeon, “Laser treatments and vitreous surgery have nearly eliminated the blinding complications of proliferative diabetic retinopathy for decades. However, over half a million diabetics with the background form of diabetic retinopathy develop diabetic macular edema (DME), threatening their fine vision, and their ability to read and drive. Precise focal laser treatment for DME typically only slowed visual loss. In 2010, Lucentis® was approved for treatment of DME and quickly became the standard of care, stabilizing or improving vision two lines in two years in about 1/3 of patients but often requiring monthly injections. We are thrilled to now have a second FDA-approved medication, Ozurdex, for treatment of DME,” Dr. Maisel continues. “The mechanism of action is different from Lucentis and it may act in concert for challenging cases with duration of action of up to six months.”

Rodney P. Coe, M.D., an associate retinal specialist with the Retina Group of New York, states that, “Our group has over 5 years of experience administering Ozurdex for treatment of posterior uveitis and retinal vascular occlusions. Ozurdex is administered in the eye during routine office visits and has proven to be safe and effective. Diabetic macular edema involves complex mechanisms, and having an additional treatment option broadens our ability to control this condition.”

For more information about Ozurdex treatment for DME, or to schedule a consultation with the Retina Group of New York, please call 516.939.6100 or 631-273-1818. An NIH video, "Diabetic Retinopathy" can be viewed on YouTube.

About The Retina Group of New York
The Retina Group of New York is composed of Board Certified Ophthalmologists with additional subspecialty training in vitreous and retinal surgery and medical retinal diagnosis and treatment. The group provides eye care for patients with retinal problems such as diabetic retinopathy, macular degeneration, retinal vascular disease, retinal detachments, vitreoretinal interface disorders such as VMA, macular puckers and holes, surgical complications, uveitis and second opinions. Members of the group holds staff privileges at seven area hospitals, teaching appointments and served as a Corporate Advisory Board member for the Foundation of the American Academy of Ophthalmology (AAO), the Juvenile Diabetes Foundation Medical Advisory Board and the AAO Instrument and Device and Low Vision Committees. They have received research grants from the U.S. Public Health Service and the National Institute of Health and represented the National Society to Prevent Blindness at the ANSI Z-80 committee helping to establish many ophthalmic industry standards.

Read the full story at http://www.prweb.com/releases/diabetic/retinopathy/prweb12008533.htm.


'/>"/>
Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related medicine news :

1. Antibiotics Linked to Retinal Detachment Risk
2. Gene Signal presents data at ARVO 2012 showing topical aganirsen is active in retinal disease
3. New type of retinal prosthesis could better restore sight to blind, Stanford study says
4. Prosthetic retina offers simple solution to restoring sight
5. Study finds novel therapy that may prevent damage to the retina in diabetic eye diseases
6. Retinal Device Restores Sight to Blind Mice
7. Retina Specialty Institute Gives Patients Something to Look Forward to in Crestview
8. UCIs Gavin Herbert Eye Institute receives $3 million for retinal degeneration research
9. San Antonio Eye Center Welcomes Retina Specialist Dr. Calvin Christopher Brown
10. Nationally-Recognized Retinal Expert Returns to Gainesville, Joins Retina Specialty Institute
11. Preferred retinal location may aid rehabilitation in patients with central vision loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... ... ... “Finn Mouseson”: follows the exciting story of a mouse as the need ... on a journey that will show that friends are to be gathered but home ... and illustrator, Melody Gersonde-Mickelson, who has earned a bachelor’s degree in Fine Arts from ...
(Date:9/20/2017)... ... September 20, 2017 , ... “Psalms of Humidity”: is a fascinating depiction of ... the readers one step closer to God. “Psalms of Humidity” is the creation of ... have been made within his life are the very same things that have shaped ...
(Date:9/20/2017)... ... 20, 2017 , ... “They Sang At Her Funeral”: a tale of murder ... the skeletons in their closets. “They Sang At Her Funeral” is the creation of ... and married with five children and twelve grandchildren. Before becoming a writer, Annalise had ...
(Date:9/19/2017)... ... September 19, 2017 , ... Only a few physicians were selected ... own Ross A. Clevens, MD, FACS . The founder and medical director of ... Reconstructive Surgeon who trained at Yale, Harvard and the University of Michigan. He has ...
(Date:9/19/2017)... ... 19, 2017 , ... Trusted debt-reduction firm CreditAssociates, LLC has announced two important ... excess of $835 million in resolved debt for its clients. , Credit card debt, ... the categories of debt settled by the company. With more than a decade of ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)... , Sept. 7, 2017 NuvoAir (formerly ... Spirometer, announced today a partnership with Novartis Pharma AG to ... NuvoAir,s position as the leading mobile spirometry platform and Novartis, ... ... ...
(Date:9/6/2017)... PDI , a leader in infection prevention products and ... focused on the role of chlorhexidine gluconate (CHG) in ... Annual Scientific Meeting of the Association for Vascular Access. ... Phoenix Convention Center in ... feature PDI,s Prevantics® Device Swab as the ...
(Date:9/5/2017)... 2017  Getinge, a leading global provider of ... donation program -- "Color for the Kids!" -- ... research by The Children,s Heart Foundation. Pediatric patients ... are encouraged to download a coloring picture at ... to the gallery on the website. For each ...
Breaking Medicine Technology: